Your browser is no longer supported. Please, upgrade your browser.
NEW! We've added Bitcoin charts to our Forex section. ×
Settings
NVS [NYSE]
Novartis AG
Index- P/E23.98 EPS (ttm)4.33 Insider Own- Shs Outstand2.70B Perf Week0.10%
Market Cap280.36B Forward P/E18.91 EPS next Y5.49 Insider Trans- Shs Float431.79M Perf Month-1.56%
Income10.66B PEG3.07 EPS next Q1.21 Inst Own10.00% Short Float0.66% Perf Quarter3.68%
Sales53.63B P/S5.23 EPS this Y16.20% Inst Trans0.31% Short Ratio2.15 Perf Half Y11.55%
Book/sh29.39 P/B3.53 EPS next Y6.23% ROA10.50% Target Price110.13 Perf Year18.68%
Cash/sh5.00 P/C20.76 EPS next 5Y7.80% ROE18.60% 52W Range81.85 - 105.82 Perf YTD15.25%
Dividend2.67 P/FCF76.12 EPS past 5Y3.20% ROI10.50% 52W High-1.86% Beta0.43
Dividend %2.57% Quick Ratio1.20 Sales past 5Y3.50% Gross Margin67.70% 52W Low26.87% ATR1.25
Employees133413 Current Ratio1.40 Sales Q/Q-2.00% Oper. Margin22.70% RSI (14)54.68 Volatility0.71% 1.09%
OptionableYes Debt/Eq0.29 EPS Q/Q23.50% Profit Margin24.50% Rel Volume0.47 Prev Close104.79
ShortableYes LT Debt/Eq0.19 EarningsApr 23 BMO Payout50.90% Avg Volume1.32M Price103.85
Recom1.80 SMA200.67% SMA501.86% SMA20010.21% Volume615,920 Change-0.90%
Nov-16-09Initiated Deutsche Securities Buy
Nov-12-09Initiated Barclays Capital Underweight $48
Sep-30-09Upgrade Citigroup Hold → Buy
Sep-15-09Upgrade Jefferies & Co Hold → Buy
Jul-17-09Upgrade JP Morgan Neutral → Overweight
Mar-17-09Initiated Credit Suisse Neutral
Feb-27-09Reiterated Credit Suisse Neutral $14 → $7
Jan-26-09Initiated Jefferies & Co Hold
Sep-23-08Upgrade Credit Suisse Underperform → Neutral
Aug-06-08Downgrade JP Morgan Overweight → Neutral
Jun-12-08Downgrade HSBC Securities Neutral → Underweight $52 → $49
Jun-04-08Upgrade Cowen & Co Neutral → Outperform
May-09-08Upgrade Bernstein Mkt Perform → Outperform
Apr-08-08Downgrade Bear Stearns Outperform → Peer Perform
Feb-29-08Initiated Cowen & Co Neutral
Feb-29-08Downgrade HSBC Securities Neutral → Underweight
Sep-06-07Initiated UBS Buy
Jul-18-07Downgrade Credit Suisse Neutral → Underperform
Jun-01-07Reiterated Prudential Overweight $64 → $62
Apr-02-07Reiterated Banc of America Sec Buy $66 → $65
May-22-15 11:50AM  Novartis Announces Positive Data on Oncology Drug Afinitor - Analyst Blog
09:00AM  Novartis' Summer Blockbuster LCZ696 Gains A Name, Skips An Advisory Panel at Forbes
May-15-15 07:25PM  Buckingham's Top Four New Buys of First Quarter Go Up in Price
02:22PM  Why Clovis is Getting Clobbered at Barrons.com
May-14-15 07:13AM  Is Sir Andrew Witty The Person To Lead A Major Pharmaceutical Company? at Forbes
May-13-15 04:20AM  Possible Investment Contest
May-12-15 04:41PM  Ligand Pharmaceuticals Tops Q1 Earnings, Affirms View - Analyst Blog
09:06AM  Mylans Share Price Declines 3% on 1Q15 Earnings
08:31AM  GSK's Curious Oncology Research Position -- A Recipe For Failure? at Forbes
May-11-15 06:54PM  Mylan Chairman Said to Consider Perrigo Sweeteners to Make Deal at Bloomberg
04:50PM  Novartis' Zykadia Approved in the EU for Lung Cancer - Analyst Blog
01:13PM  GlaxoSmithKline: Out of step at Financial Times
May-08-15 03:25PM  Amgen wins injunction against Novartis' biosimilar drug at bizjournals.com
12:06PM  Pfizer Revenues Hit by Lost Exclusivity in 1Q15
12:06PM  Pfizers Exposure to Overseas Markets Soaks 1Q15 Revenues
08:45AM  Pharmalot.. Pharmalittle.. As the Weekend Nears: We're Catching up on Amgen, Sanofi and Much More!! at The Wall Street Journal
01:11AM  [$$] Business Watch: News Digest at The Wall Street Journal
May-07-15 08:12PM  Business Watch: News Digest at The Wall Street Journal
05:41PM  Novartis 'biosimilar' drug blocked by U.S. appeals court Reuters
03:10PM  Glaxo's (GSK) Q1 Earnings Fall Y/Y; Gives Five-Year View - Analyst Blog
02:41PM  Novartis AG's 'biosimilar' drug sale blocked by U.S. appeals court Reuters
01:50PM  Court Blocks Novartis Copy of Amgen Cancer-Care Drug at The Wall Street Journal
May-06-15 06:08PM  Today's Top 5 Stock Picks: Undervalued Large-Caps at Barrons.com
01:33PM  GSK's Sturdy Strategy Leaves Investors Waiting at The Wall Street Journal
12:53PM  GlaxoSmithKline Won't Sell Its HIV Drugs Unit, Cuts Shareholder Payout at TheStreet
12:49PM  Glaxo Q1 Earnings Miss, But 5-Year Guidance Strong at Investor's Business Daily
12:33PM  GSK Cuts Return to Shareholders From Novartis Deal at The Wall Street Journal
11:48AM  Glaxo Starts Singing Different Tune on Threat of Generic Advair at Bloomberg
10:23AM  GlaxoSmithKline opts to hold on to HIV business
10:06AM  GSK scraps plan to list HIV drugs business and shields dividend
09:40AM  Glaxo Abandons HIV-Unit Spinoff Plan, Reduces Capital Payout
09:06AM  Shares Rise 2% after Novartis Posts 1Q15 Earnings
08:15AM  GSK drops plans for IPO of HIV drugs unit at Financial Times
07:22AM  GSK rules out HIV spinout as generics hit results at CNBC
07:20AM  Glaxo Cuts Payment to Investors as Earnings Miss Estimates at Bloomberg
May-05-15 10:06PM  Is Novartis an Up-and-Coming Oncology Powerhouse?
09:06PM  Why Novartiss Operating Margins Expanded in 1Q15
09:30AM  LyondellBasell, Container Store, GlaxoSmithKline, Novartis and Genocea Biosciences highlighted as Zacks Bull and Bear of the Day - Press Releases
07:02AM  The Cancer Drug Market Just Hit $100 Billion And Could Jump 50% In Four Years at Forbes
May-04-15 12:54PM  Incyte Posts Wider-than-Expected Q1 Loss, Jakafi Grows - Analyst Blog
May-02-15 12:01AM  Novartis Looks Much Healthier at Barrons.com
May-01-15 05:47PM  Express Scripts unit to pay $60 mln over Novartis kickbacks, US says Reuters
03:06PM  Express Scripts to Pay $60M to Settle Novartis Kickback Scheme at The Wall Street Journal
01:35PM  This Cheap REIT Is a Safe Bet on Life Sciences, Tech at Barrons.com
08:58AM  Express Scripts unit to pay $45 million to U.S. over Novartis kickback scheme Reuters
07:03AM  Doubts grow over GlaxoSmithKline's $6 bln capital return plan
Apr-30-15 03:00PM  Incyte (INCY) Earnings Report: Q1 2015 Conference Call Transcript at TheStreet
12:11PM  Biotech's boom fuels real estate here at CNBC
10:09AM  Teva Beats on Q1 Earnings by Wide Margin, Ups View - Analyst Blog
09:05AM  Strength of the US Dollar Takes a Toll on Novartis Revenues
09:05AM  Novartiss Adjusted Earnings per Share Up 21.7% in 1Q15
Apr-29-15 04:15PM  Merck & Co. (MRK) Earnings Analysis: By the Numbers
03:44PM  Pfizer (PFE) Earnings Analysis: By the Numbers
03:23PM  Bristol-Myers Squibb (BMY) Earnings Analysis: By the Numbers
03:06AM  Teva 1Q15 Earnings Preview: Stock Up 10.3% since Last Quarter
Apr-28-15 01:33PM  5 Biotech Stocks to Avoid After Monday's Slump - Analyst Blog
Apr-27-15 03:02PM  ImmunoGen skids after disclosing drug development setbacks
11:26AM  Akorn Downgraded, Stock Falls On 'Credibility Gap' at Investor's Business Daily
10:38AM  Novartis announces Phase III study of Arzerra® met primary endpoint of improved progression-free survival in patients with relapsed CLL » at noodls
Apr-24-15 02:45PM  Johnson & Johnsons Revenues Take a Hit with Stronger Dollar
02:44PM  Johnson & Johnson Posts Earnings, Lowers EPS Guidance on April 14
02:35PM  Biogen Q1 Misses Estimates As Tecfidera Stalls at Investor's Business Daily
12:30PM  AT&T and eBays Earnings Led the Stock Market Rally on April 23
11:07AM  Novartis CEO Joseph Jimenez Nominated to GM Board at noodls
11:03AM  The 10 global companies that get diversity: Study at CNBC
10:00AM  Novartis (NVS) Beats on Earnings in Q1, View Reiterated - Analyst Blog
04:41AM  Lilly (Eli( (LLY) Earnings Report: Q1 2015 Conference Call Transcript at TheStreet
04:12AM  Novartis AG (NVS) Earnings Report: Q1 2015 Conference Call Transcript at TheStreet
Apr-23-15 12:06PM  AQR Capital Enhances Pfizer Holdings by 33%
11:46AM  AbbVie Beats Q1 Estimates; Novartis, Alexion Mixed at Investor's Business Daily
10:00AM  Drug Companies Pin Hopes On TrialReach To Enroll Patients In Clinical Trials Faster at Forbes
08:12AM  Early movers: PBR, MMM, CAT & more at CNBC
08:11AM  Europe shares fall on soft PMIs, Michelin gains at CNBC
07:39AM  LLY CFO: Here's what's driving profits
06:20AM  European Stocks Drop After Manufacturing, Services Miss Estimates
04:12AM  Novartis Reports First-Quarter Profit That Beats Estimates
03:57AM  Novartis starts to reap rewards of revamp at Financial Times
03:05AM  Novartis (NVS) Beats on Earnings & Revenues - Tale of the Tape
02:58AM  Divestment gains boost net earnings at drug company Novartis
02:09AM  Deutsche Bank Said to Pay EU2B to End Libor Probes at Bloomberg
02:07AM  European Index Futures Climb as Novartis Earnings Beat Estimates at Bloomberg
02:07AM  Novartis warns of currency drag on 2015 earnings at CNBC
02:03AM  Novartis 1Q Sales $11.9B; Est. $12.8B at Bloomberg
01:58AM  Unipetrol Increases First-Quarter Net on Higher Refinery Margins at Bloomberg
01:57AM  Novartis Profit Boosted Disposals at The Wall Street Journal
01:44AM  CaixaBank First-Quarter Profit Doubles Amid Higher Commissions at Bloomberg
01:17AM  Novartis Reports First-Quarter Earnings That Beat Estimates at Bloomberg
01:08AM  Novartis delivered sales growth (cc), significant margin expansion (cc) and strong innovation in Q1; now with a more focused portfolio » at noodls
Apr-22-15 07:20PM  CSL's CFO to head flu vaccines business AAP
09:15AM  Amgen Beats on Q1 Earnings & Revenues, Ups Earnings View - Analyst Blog
Apr-21-15 03:12PM  Will Eli Lilly (LLY) Beat Earnings in 1Q Despite Generics? - Analyst Blog
02:57PM  Juno Therapeutics Gets Lift From Cancer Test Results at Investor's Business Daily
02:50PM  Will Novartis' (NVS) Earnings Disappoint This Quarter? - Analyst Blog
11:35AM  Teva Bids $40 Billion For Mylan, But May Need More at Investor's Business Daily
01:24AM  Data at AAN showed Gilenya® high efficacy in achieving 'no evidence of disease activity' in previously-treated highly-active MS patients » at noodls
12:14AM  Overheard: Allergic Reaction at The Wall Street Journal
Apr-20-15 05:41PM  Novartis solid tumor 'CAR T cell' still holds promise - researcher
04:57PM  Juno stock drops on report of lackluster immunotherapy results on solid tumors at bizjournals.com
04:36PM  Allergic Reaction -- Overheard at The Wall Street Journal
02:42PM  Big biotech movers: Juno & Kite
Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. Its Pharmaceuticals division offers patented prescription medicines in various therapeutic areas, such as oncology, cardio-metabolic, immunology and dermatology, retina, respiratory, neuroscience, and established medicines. The company's Alcon division provides various eye care products, including surgical, ophthalmic pharmaceuticals, and vision care products; ophthalmic surgical equipment, instruments, disposable products, and intraocular lenses; medicines to treat chronic and acute diseases of the eye; over-the-counter medicines for the eye; and contact lenses and lens care products. Its Sandoz division offers generic pharmaceuticals comprising active ingredients and finished dosage forms of pharmaceuticals; active pharmaceutical ingredients and intermediates primarily antibiotics; protein or biotechnology-based products; and cytotoxic products for the hospital market, as well as biotech manufacturing services to other companies. The company distributes its OTC products through various channels, such as pharmacies, food, drug, and mass retail outlets. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Novartis Bioventures Ltd10% OwnerSep 22Buy15.00325,0004,875,0004,644,328Sep 24 05:42 PM